Clinical Trials Logo

Filter by:
NCT ID: NCT05989347 Not yet recruiting - Breast Cancer Clinical Trials

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

Start date: June 2024
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to assess metabolic plasma markers of insulin resistance in patients with early-stage HER2-negative breast cancers receiving dapagliflozin concomitant with neoadjuvant therapy.

NCT ID: NCT05989308 Not yet recruiting - Health Technology Clinical Trials

MyChart Proxy Outreach to Parents (MyPOP)

MyPOP
Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this randomized controlled trial is to assess the extent to which different modes of contacting parents who have not yet enabled to access to their children's medical records will result in greater proxy access. The main questions the study aims to answer are: - will outreach via text or patient portal message result in more parents having access than usual care (which is in-office suggestions to get access). - which mode - text or portal - will get more parents access. Participants will get a text message, or a portal message through their own patient portal, or no message. The investigators will check access to see which group has increased more during the study period.

NCT ID: NCT05989256 Not yet recruiting - Hypoglycemic Events Clinical Trials

Developing a Model to Predict Inpatient Hypoglycemic Episodes

Start date: October 2024
Phase: N/A
Study type: Interventional

This study will create a new model to predict hypoglycemic events in diabetic inpatients on anti-hyperglycemic therapy using retrospective data with the goal of developing a model that will accurately predict hypoglycemic episodes in the patient population - piloting the risk score that was developed in the context of EndoTool being rolled out at the institution, to determine the feasibility and acceptability of viewing the risk score in the Electronic Health Record

NCT ID: NCT05988463 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Open-Label Dose-Escalation Treatment Study of Patients With IPF

DIAMOND
Start date: February 1, 2024
Phase: Phase 1
Study type: Interventional

Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic lung disease resulting in increasing shortness of breath, cough, and low oxygen levels as a result of lung tissue scarring . The goal of this open-label (no placebo) study is to evaluate the safety and tolerability of artesunate at three different doses in patients with IPF. The secondary goals are to explore the blood biomarkers present in IPF patients at the beginning of the study and to study how those biomarkers change following treatment with artesunate. Participants will have 7 visits to the study site over 20 weeks which will include physician exams, vital signs, questionnaires, research and safety blood samples, and taking artesunate capsules by mouth for 12 weeks. Artesunate is used world-wide for the treatment of severe malaria but has also been found to block specific proteins that cause lung scarring and may provide an additional treatment to slow the fibrotic process in the lung and improve survival and quality of life for patients with IPF.

NCT ID: NCT05988385 Not yet recruiting - Clinical trials for Obstructive Sleep Apnea

The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study

ESSENTIAL
Start date: January 2024
Phase: N/A
Study type: Interventional

The Effects of Successful OSA TreatmENT on Memory and AD BIomarkers in Older AduLts (ESSENTIAL) study is a 5-year, multicenter randomized open-label trial that will screen 400 cognitively normal older adults recruited from well-established sleep clinics at 4 academic medical centers, with newly diagnosed moderate-severe OSA. An expected 200 OSA patients will be then randomized to one of two groups: i) a 3-month OSA treatment by any combination of PAP, OAT, and positional therapy that results in an "effective" AHI4%< 10/hour and AHI3A<20/hour (see below); ii) a waitlist control group to receive treatment at the conclusion of the 3-month intervention period. Both groups will continue follow-up for 24 months on stable therapy to determine if sustained improvements in sleep are associated with improvement in cognitive function and AD biomarkers.

NCT ID: NCT05987956 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms

Drugs-SNPs
Start date: March 8, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Explore the relationship between drug target ALK gene single nucleotide polymorphisms and ALECENSA - Alectinib therapeutic-effects in patients with non-small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms and ALECENSA - Alectinib side-effects in patients with non-small cell lung cancer, based on Oxford precisely sequencing drug targets' genes.

NCT ID: NCT05987592 Not yet recruiting - Migraine Clinical Trials

BE WELL With Migraine: Brain Education and WELLness With Migraine

Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this randomized clinical trial is to evaluate two different non-drug, virtual treatment options designed to improve the lives of patients with migraine. Both interventions involve 8 weekly sessions and an online platform with additional content and learning. Participants can stay on all their medications during this study. Information from this study may help determine how to better treat migraine.

NCT ID: NCT05987059 Not yet recruiting - Clinical trials for Preconception Health

Involving Communities in Addressing the Maternal Health Crisis: Making an IMPACT

Start date: August 2023
Phase: Phase 2
Study type: Interventional

With support from the National Heart, Lung, and Blood Institute, The Center for Maternal Health Equity at Morehouse School of Medicine is conducting a research study to test the implementation of Pre-Pregnancy Counseling in community-based settings.

NCT ID: NCT05987007 Not yet recruiting - Sleep Disturbance Clinical Trials

Sleep Interventions and Neurocognitive Outcomes

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

This protocol focuses on the effect of sleep interventions on improving sleep and building cognitive/brain resilience in older adults with amnestic mild cognitive impairment and sleep disturbance. Two sleep interventions, cognitive behavioral therapy for insomnia (CBTI) and acoustic slow-wave activity enhancement (SWAE), will be utilized in a pilot randomized clinical trial in which participants are randomized to different treatment groups (CBTI or SWAE). Participants will be assessed over a 6-month period in order to examine the impact of sleep treatments on neuropsychological outcomes and cognitively mediated everyday functioning.

NCT ID: NCT05986578 Not yet recruiting - Clinical trials for Cocaine Use Disorder

Identifying Electrophysiological Targets for Transcranial Magnetic Stimulation in Cocaine Use Disorder

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to assess effects of intermittent theta burst stimulation (iTBS) to left dorsolateral prefrontal cortex (dlPFC) and dorsomedial prefrontal cortex (dmPFC) compared to sham on electrophysiological indices of reward sensitivity and motivated attention in adults with cocaine use disorder.